Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Satellos Bioscience Inc Ordinary Shares V.MSCL

Alternate Symbol(s):  ICOTF

Healthcare Biotechnology
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSXV:MSCL)

Fundamentals Snapshot (TSXV:MSCL)

Current News (TSXV:MSCL)

Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit

Newsfile 5 days ago

Satellos Bioscience Announces Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures of up to $2.25 Million

Newsfile 6 days ago

Satellos Bioscience (TSXV:MSCL) informs of new results around SAT-3153

Brieanna McCutcheon  11 days ago

Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 As a Potential Treatment for Duchenne Muscular Dystrophy

Newsfile 12 days ago

Satellos Bioscience Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model

Newsfile February 6, 2023

Satellos Bioscience Announces Development Candidate

Newsfile January 3, 2023

Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights

Newsfile November 23, 2022

Satellos Bioscience (TSXV:MSCL) advances compounds to the next stage of development

Brieanna McCutcheon  November 3, 2022

Satellos Bioscience Announces Advancement of Compounds to Next Stage of Development

Newsfile November 3, 2022
View More News ››

Opinion & Analysis (TSXV:MSCL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:MSCL)

Business Update: CTO Phil Lambert Discusses SAT-3153 Results

Business Update: Satellos Bioscience $MSCL with CTO Philip Lambert - https://youtu.be/OZAfLhS9WB4   Chief Technology...
bmreed - 7 days ago

RE:Zacks-Fireside Chat With Frank Gleeson-02/13/2023

Zacks - Small-Cap Research - Outlook - David Bautz PhD https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_02072023_MSCLF...
G1945V - February 17, 2023

Zacks-Fireside Chat With Frank Gleeson-02/13/2023

A Fireside Chat With Frank Gleeson, MBA - Co-Founder, CEO, And Board Member Of Satellos Bioscience Price Target 70 cents US https:/...
G1945V - February 17, 2023

News Story Feb 6 2023

Satellos Bioscience Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model G1945V
G1945V - February 6, 2023

.012 pre consolidation

KEEP UP THE GOOD WORK azz CLOWNS 
Drambuey - November 1, 2022

Video Recap - $MSCL CEO Frank Gleeson & CTO Phil Lambert

Webinar Recap: Satellos Bioscience (MSCL) w CEO Frank Gleeson and CTO Phil Lambert - Pitch, Deep Dive and Q&A - https://youtu.be...
bmreed - October 24, 2022
View more Bullboard ››

RevoluGROUP Canada Inc.

RevoluGROUP Canada Inc.

RevoluGROUP Canada Inc is a multi-vertical Fintech Neobank generating revenue via its RevoluPAY mobile EU PSD2, FINTRAC & USA ...
View More »